ABMC Reports Third Quarter Results.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ:ABMC) today announced the unaudited results for the three and nine months ending September 30, 2006.

The Company reported 2006 third quarter net sales of $3,564,000 compared to $3,570,000 in the same quarter in 2005. Net sales for the third quarter of 2006 were relatively unchanged from the third quarter of 2005. For the nine months ended September 30, 2006, net sales were $10,657,000, an increase of $342,000, or 3.3%, when compared to net sales of $10,315,000 reported for the first nine months of 2005.

The Company reported an operating loss of $4,000 for the third quarter of 2006 and operating income of $144,000 for the nine months ending September 30, 2006, compared to operating loss of $25,000 for the third quarter and operating income of $223,000 for the nine months ended September 30, 2005.

Net loss for the third quarter of 2006 was $16,000, or $0.00 per share. This third quarter net loss compares to a net loss of $39,000, or $0.00 per share, for the same period last year. For the first nine months of 2006, the Company reported net income of $92,000 or $0.00 per share, compared to $183,000 or $0.01 per share for the same period a year ago.

Commenting on the financial results, ABMC Chief Executive Officer Stan Cipkowski stated, "Certain orders that we expected in the third quarter were delayed and unfortunately they were not received in time to positively impact our third quarter sales. These orders have already started coming in and based on other expected orders for the fourth quarter, we remain confident that we will have a strong fourth quarter that will bring us closer to our financial objectives."

Cipkowski added, "We continue to deal with price pressure in our markets caused by foreign manufacturers and we are pleased that as a result of ABMC's continued efforts to control manufacturing and operating cost increases, our operating results did improve when comparing quarter over quarter numbers even with this pressure."

For more information on ABMC or its drug testing products, please visit www.abmc.com .

Conference Call

The Company will host a conference call and webcast to discuss the Third Quarter results on Thursday, November 2, 2006 at 11:00 a.m. (EST). Investors and interested parties are invited to participate. The call will be broadcast live over the Internet at www.abmc.com/investor/ . The webcast will be listen-only mode. Listeners are requested to be online at least fifteen minutes early to register, as well as to download and install any complimentary audio software that might be required. To ask questions, you are invited to participate by phone. Within the United States, dial 1-866-321-6651 and internationally dial 1-416-642-5212. The call will be available for replay at www.abmc.com/investor/ for 30 days.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen[R], Rapid One[R], Rapid TEC[R], RDS[R] InCup[R] and Rapid TOX[TM] products test for the presence or absence of drugs of abuse in urine, while OralStat[R] tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader[TM] is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2005, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

[TABLE OMITTED]
[TABLE OMITTED]